Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Jill Maaske"'
Autor:
Magdalena E. Sobieszczyk, Jill Maaske, Ann R. Falsey, Stephanie Sproule, Merlin L. Robb, Robert W. Frenck Jr., Hong-Van Tieu, Kenneth H. Mayer, Lawrence Corey, Kathleen M. Neuzil, Tina Tong, Margaret Brewinski Isaacs, Holly Janes, Himanshu Bansal, Lindsay M. Edwards, Justin A. Green, Elizabeth J. Kelly, Kathryn Shoemaker, Therese Takas, Tom White, Prakash Bhuyan, Tonya Villafana, and Ian Hirsch, on behalf of the AstraZeneca AZD1222 Clinical Study Group
Publikováno v:
The Journal of Clinical Investigation, Vol 132, Iss 18 (2022)
Background We report updated safety, efficacy, and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) from an ongoing phase 3 trial.Methods Adults at increased risk of SARS-CoV-2 infection were randomized (2:1), stratified by age, to receive 2 doses of AZD1
Externí odkaz:
https://doaj.org/article/0223bfbe518d427787c488021708dfaa
Autor:
Juan P. Frias, Paul D. Hockings, Lars Johansson, Jill Maaske, Lisa J. Suchower, John P.H. Wilding, Nayyar Iqbal
Publikováno v:
Diabetes, Obesity and Metabolism. 24:61-71
AIM To report the results of a 104-week extension to a 52-week study in which dapagliflozin plus saxagliptin (DAPA+SAXA) improved glycaemic control, liver fat and metabolic variables compared with glimepiride (GLIM) in participants with type 2 diabet
Autor:
Juan P. Frias, Donald C. Simonson, Marcia A. Testa, Guillermo Gonzalez‐Galvez, Anne L. Peters, Jill Maaske, Nalina Dronamraju, Eva Johnsson, Ricardo Garcia-Sanchez
Publikováno v:
Diabetes, Obesity & Metabolism
Aims To evaluate the efficacy and safety of dapagliflozin (DAPA) + saxagliptin (SAXA) compared with glimepiride (GLIM) in patients with type 2 diabetes who were inadequately controlled [glycated haemoglobin (HbA1c) 7.5–10.5% (58–91 mmol/mol)] on
Autor:
Nalina Dronamraju, Paul D. Hockings, Lars Johansson, John P.H. Wilding, Jill Maaske, Eva Johnsson, Ricardo Garcia-Sanchez
Publikováno v:
Diabetes, Obesity & Metabolism
DIABETES OBESITY & METABOLISM
DIABETES OBESITY & METABOLISM
Aim To assess the effects of dapagliflozin plus saxagliptin plus metformin versus glimepiride plus metformin on liver fat (proton density fat fraction) and visceral and subcutaneous adipose tissue volumes over 52 weeks of treatment. Materials and met
Autor:
Ann R, Falsey, Magdalena E, Sobieszczyk, Ian, Hirsch, Stephanie, Sproule, Merlin L, Robb, Lawrence, Corey, Kathleen M, Neuzil, William, Hahn, Julie, Hunt, Mark J, Mulligan, Charlene, McEvoy, Edwin, DeJesus, Michael, Hassman, Susan J, Little, Barbara A, Pahud, Anna, Durbin, Paul, Pickrell, Eric S, Daar, Larry, Bush, Joel, Solis, Quito Osuna, Carr, Temitope, Oyedele, Susan, Buchbinder, Jessica, Cowden, Sergio L, Vargas, Alfredo, Guerreros Benavides, Robert, Call, Michael C, Keefer, Beth D, Kirkpatrick, John, Pullman, Tina, Tong, Margaret, Brewinski Isaacs, David, Benkeser, Holly E, Janes, Martha C, Nason, Justin A, Green, Elizabeth J, Kelly, Jill, Maaske, Nancy, Mueller, Kathryn, Shoemaker, Therese, Takas, Richard P, Marshall, Menelas N, Pangalos, Tonya, Villafana, Antonio, Gonzalez-Lopez, Barry S, Zingman
Publikováno v:
The New England Journal of Medicine
The New England journal of medicine, vol 385, iss 25
The New England journal of medicine, vol 385, iss 25
Background The safety and efficacy of the AZD1222 (ChAdOx1 nCoV-19) vaccine in a large, diverse population at increased risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the United States, Chile, and Peru has not been
Publikováno v:
Diabetes. 67
Add-on therapy with a single oral antihyperglycemic agent is often insufficient to provide glycemic control in patients with type 2 diabetes (T2D) uncontrolled on metformin (MET) monotherapy. This randomized, parallel-group, double-blind, 52-week tri
Autor:
Paul D. Hockings, John P.H. Wilding, Lars Johansson, Eva Johnsson, Jill Maaske, Ricardo Garcia-Sanchez
Publikováno v:
Diabetes. 67
Oral administration of a fixed-dose combination of the SGLT2 inhibitor dapagliflozin (DAPA) and the DPP-4 inhibitor saxagliptin (SAXA) is approved for improving glycemic control in adult patients with type 2 diabetes (T2D). A 52-week, multicenter, ra
Autor:
Yoojin Kim, Alaleh Mazhari, Valeriu Neagu, Susan DeLange, Dan V. Mihailescu, Mary Ann Emanuele, Weihua Gao, Sofronio C. Ramirez, David S. Baldwin, Nicholas V. Emanuele, Jill Maaske
Publikováno v:
Endocrine Practice. 20:894-900
Objective To analyze the relationship between glycemic control after renal transplantation and subsequent graft function and complications. Methods We conducted a retrospective chart review of 202 consecutive patients undergoing kidney transplantatio